50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

EU says Pfizer to deliver over 200 million vaccine doses in second quarter

Published 03/16/2021, 07:12 AM
Updated 03/16/2021, 07:15 AM
© Reuters. COVID-19 vaccination campaign in Nice
PFE
-
JNJ
-
AZN
-
MRNA
-

BRUSSELS (Reuters) - The European Commission expects to receive more than 200 million doses of COVID-19 vaccine from Pfizer (NYSE:PFE) and BioNTech in the second quarter, it said on Tuesday, putting the European Union on course to meet its inoculation target.

The EU aims to vaccinate at least 255 million people, or 70% of its adult population, by the end of the summer.

It has faced criticism of a slow rollout amid supply delays from some drugmakers, hiccups in vaccination plans and the suspension of inoculations using the AstraZeneca (NASDAQ:AZN) vaccine due to potential health issues.

The new expected deliveries from Pfizer include 10 million doses originally expected in the third and fourth quarters, the Commission said.

"These accelerated 10 million doses will bring the total doses of BioNTech-Pfizer in quarter two up to over 200 million," EU Commission President Ursula von der Leyen said, revealing for the first time the volume of doses expected from Pfizer in the April-June quarter.

Pfizer on Tuesday confirmed the EU statement regarding second-quarter supply.

"This is very good news. It gives member states room to manoeuvre and possibly fill gaps in deliveries," von der Leyen said.

The additional doses would be moved forward from an option of 100 million doses in a second contract the EU signed in January with Pfizer and BioNTech, the EU statement said.

In total the EU has booked 600 million doses from the two companies in two separate contracts.

It is unclear whether this announcement could lead to changes in the EU's overall delivery forecasts. The Commission said last week it expected 300 million doses in the second quarter from all the vaccine makers it had contracts with.

The bloc in the second quarter expects 55 million doses from Johnson & Johnson (NYSE:JNJ) and 35 million from Moderna (NASDAQ:MRNA), according to a delivery schedule published by the Italian government and an internal document on supply forecasts from Germany's health ministry.

© Reuters. COVID-19 vaccination campaign in Nice

AstraZeneca last week announced it aimed to deliver to the 27-nation bloc 70 million doses in the second quarter from its original contractual obligation of 180 million.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.